Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Bayer |
---|---|
Information provided by: | Bayer |
ClinicalTrials.gov Identifier: | NCT00350051 |
The purpose of this study is to evaluate whether treatment with a new drug called ZK-Epothilone (ZK-Epo) given with prednisone in patients with androgen-independent prostate cancer, who have not had previous chemotherapy, is safe and helps to decrease PSA (Prostate-specific antigen) levels.
Condition | Intervention | Phase |
---|---|---|
Prostate Cancer |
Drug: SH-Y03757A (ZK-Epothilone; ZK-219477) with prednisone |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study |
Official Title: | Phase 2 Study of ZK-Epothilone (ZK-Epo; ZK219477) Plus Prednisone as First-Line Chemotherapy in Patients With Metastatic Androgen-Independent Prostate Cancer |
Enrollment: | 46 |
Study Start Date: | August 2006 |
Estimated Study Completion Date: | May 2009 |
Estimated Primary Completion Date: | May 2009 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
Arm 1: Experimental |
Drug: SH-Y03757A (ZK-Epothilone; ZK-219477) with prednisone
Chemotherapy for hormone refractory prostate cacner; 16mg/m2 (up to 32mg/m2 max) IV on day 1 or each 21 day cycle for 6 cycles or until progression or unacceptable toxicity.
|
This study has previously been posted by Berlex, Inc. and Schering AG, Germany. Berlex, Inc. has been renamed to Bayer HealthCare Pharmaceuticals, Inc., Schering AG Germany has been renamed to Bayer Schering Pharma AG, Germany.
Bayer HealthCare Pharmaceuticals, Inc.and Bayer Schering Pharma AG, Germany are the sponsors of the trial.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Male |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
United States, California | |
Fountain Valley, California, United States, 92708 | |
United States, Florida | |
Sarasota, Florida, United States, 34237 | |
United States, Maryland | |
Baltimore, Maryland, United States, 21201 | |
United States, Michigan | |
Ann Arbor, Michigan, United States, 48109-0330 | |
United States, Montana | |
Billings, Montana, United States, 59101 | |
United States, Nebraska | |
Omaha, Nebraska, United States, 68198 | |
United States, New York | |
Bronx, New York, United States, 10469 | |
United States, Ohio | |
Canton, Ohio, United States, 44718 | |
United States, Oregon | |
Portland, Oregon, United States, 97201-2999 | |
United States, Pennsylvania | |
Altoona, Pennsylvania, United States, 16601 | |
United States, Texas | |
Fort Worth, Texas, United States, 76104 | |
United States, Washington | |
Seattle, Washington, United States, 98108-1597 | |
Argentina | |
Buenos Aires, Argentina, C1405DCS | |
Buenos Aires, Argentina, C1416CRJ | |
Córdoba, Argentina, 5016 | |
Argentina, Capital Federal | |
Buenos Aires, Capital Federal, Argentina, C1406FWY | |
Buenos Aires, Capital Federal, Argentina, C1280AEB |
Study Director: | Bayer Study Director | Bayer |
Responsible Party: | Bayer Healthcare Pharmaceuticals Inc. ( Therapeutic Area Head ) |
Study ID Numbers: | 91500, 307976 |
Study First Received: | July 7, 2006 |
Last Updated: | January 9, 2009 |
ClinicalTrials.gov Identifier: | NCT00350051 |
Health Authority: | United States: Food and Drug Administration; Argentina: Administracion Nacional de Medicamentos, Alimentos y Tecnologia Medica |
Prostate cancer Metastatic androgen-independent prostate cancer |
Prednisone Prostatic Diseases Genital Neoplasms, Male Epothilones |
Urogenital Neoplasms Genital Diseases, Male Prostatic Neoplasms |
Anti-Inflammatory Agents Molecular Mechanisms of Pharmacological Action Antineoplastic Agents, Hormonal Antineoplastic Agents Mitosis Modulators Physiological Effects of Drugs Hormones, Hormone Substitutes, and Hormone Antagonists Antimitotic Agents |
Glucocorticoids Hormones Pharmacologic Actions Neoplasms Neoplasms by Site Therapeutic Uses Tubulin Modulators |